{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:19:44Z","timestamp":1790867984074,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL174038"],"award-info":[{"award-number":["R01HL174038"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL161456"],"award-info":[{"award-number":["R01HL161456"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM122741"],"award-info":[{"award-number":["T32GM122741"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA241679"],"award-info":[{"award-number":["R01CA241679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01HL165294"],"award-info":[{"award-number":["1R01HL165294"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.addr.2024.115361","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T13:13:17Z","timestamp":1718716397000},"page":"115361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations"],"prefix":"10.1016","volume":"211","author":[{"given":"Jessica","family":"Tetterton-Kellner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7154-0002","authenticated-orcid":false,"given":"Juliane","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.addr.2024.115361_b0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2024.115361_b0010","unstructured":"Statistics and Graphs | Division of Cancer Control and Population Sciences (DCCPS). Accessed May 9, 2023. https:\/\/cancercontrol.cancer.gov\/ocs\/statistics."},{"key":"10.1016\/j.addr.2024.115361_b0015","unstructured":"US Childhood Cancer Statistics - ACCO. Accessed June 6, 2023. https:\/\/www.acco.org\/us-childhood-cancer-statistics\/."},{"key":"10.1016\/j.addr.2024.115361_b0020","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/134679","article-title":"Cardiovascular effects in childhood cancer survivors treated with anthracyclines","volume":"2011","author":"Franco","year":"2011","journal-title":"Cardiol. Res. Pract."},{"key":"10.1016\/j.addr.2024.115361_b0025","unstructured":"Major Categories of Chemotherapy Agents | SEER Training. Accessed January 5, 2024. https:\/\/training.seer.cancer.gov\/treatment\/chemotherapy\/types\/major-categories.html."},{"key":"10.1016\/j.addr.2024.115361_b0030","unstructured":"Information for Health Care Providers on Infections During Chemotherapy | Preventing Infections in Cancer Patients | CDC. Accessed August 31, 2023. https:\/\/www.cdc.gov\/cancer\/preventinfections\/providers.htm."},{"issue":"7","key":"10.1016\/j.addr.2024.115361_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076272","article-title":"Radiation treatment mechanisms of cardiotoxicity: A systematic review","volume":"24","author":"Siaravas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.addr.2024.115361_b0040","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0045","first-page":"1132","article-title":"Cardiotoxicity of chemotherapy and targeted agents","volume":"11","author":"Mudd","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.addr.2024.115361_b0050","unstructured":"Types of Chemotherapy Drugs | SEER Training. Accessed September 8, 2023. https:\/\/training.seer.cancer.gov\/treatment\/chemotherapy\/types.html."},{"issue":"2","key":"10.1016\/j.addr.2024.115361_b0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","article-title":"Cardiotoxicity of cytotoxic drugs","volume":"30","author":"Schimmel","year":"2004","journal-title":"Cancer Treat. Rev."},{"issue":"36","key":"10.1016\/j.addr.2024.115361_b0060","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2024.115361_b0070","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.23908","article-title":"Mitochondrial flashes regulate ATP homeostasis in the heart","volume":"6","author":"Wang","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.addr.2024.115361_b0075","doi-asserted-by":"crossref","unstructured":"Podyacheva EY, Kushnareva EA, Karpov AA, Toropova YG. Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician. Front Pharmacol. 2021;12:670479. doi:10.3389\/fphar.2021.670479.","DOI":"10.3389\/fphar.2021.670479"},{"key":"10.1016\/j.addr.2024.115361_b0080","doi-asserted-by":"crossref","unstructured":"Lustberg MB, Kuderer NM, Desai A, Bergerot C, Lyman GH. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nat Rev Clin Oncol. May 25, 2023. doi:10.1038\/s41571-023-00776-9.","DOI":"10.1038\/s41571-023-00776-9"},{"issue":"2","key":"10.1016\/j.addr.2024.115361_b0085","doi-asserted-by":"crossref","first-page":"e2254669","DOI":"10.1001\/jamanetworkopen.2022.54669","article-title":"Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985\u20132010","volume":"6","author":"Larsen","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0090","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/2042098614529603","article-title":"Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors","volume":"5","author":"Onitilo","year":"2014","journal-title":"Ther. Adv. Drug Saf."},{"issue":"9","key":"10.1016\/j.addr.2024.115361_b0095","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006915","article-title":"Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies","volume":"6","author":"Florido","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.addr.2024.115361_b0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14740338.2023.2204228","article-title":"High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated malignancies: a pharmacovigilance study based on the FAERS database","volume":"22","author":"Ma","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular effects of the MEK inhibitor, trametinib: A case report, literature review, and consideration of mechanism","volume":"17","author":"Banks","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"issue":"5","key":"10.1016\/j.addr.2024.115361_b0110","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.addr.2024.115361_b0115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/CIRCRESAHA.117.312395","article-title":"Anthracycline cardiotoxicity","volume":"122","author":"Bernstein","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2024.115361_b0120","unstructured":"Mahmaljy H, Yelamanchili VS, Singhal M. Dilated Cardiomyopathy. In: StatPearls. StatPearls Publishing; 2024."},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4330\/wjc.v13.i1.28","article-title":"Anthracycline-induced cardiotoxicity: A case report and review of literature","volume":"13","author":"Chong","year":"2021","journal-title":"World J. Cardiol."},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12574-020-00502-9","article-title":"Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction","volume":"19","author":"Onishi","year":"2021","journal-title":"J. Echocardiogr."},{"issue":"3","key":"10.1016\/j.addr.2024.115361_b0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/ERP-16-0020","article-title":"Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy","volume":"3","author":"Boczar","year":"2016","journal-title":"Echo Res. Pract."},{"key":"10.1016\/j.addr.2024.115361_b0140","unstructured":"Cardio-Oncology Echocardiography Protocol for Anthracyclines, Trastuzumab - American College of Cardiology. Accessed June 21, 2023. https:\/\/www.acc.org\/latest-in-cardiology\/ten-points-to-remember\/2021\/03\/17\/18\/18\/bse-and-bcos-guideline-for-transthoracic."},{"issue":"3","key":"10.1016\/j.addr.2024.115361_b0270","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s43018-020-0039-1","article-title":"A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy","volume":"1","author":"Amgalan","year":"2020","journal-title":"Nat. Cancer"},{"issue":"13","key":"10.1016\/j.addr.2024.115361_b0280","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","article-title":"Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity","volume":"111","author":"Fisher","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2024.115361_b0300","doi-asserted-by":"crossref","unstructured":"Zhang Z, Peng J, Hu Y, Zeng G, Du W, Shen C. CTRP5 Attenuates Doxorubicin-Induced Cardiotoxicity Via Inhibiting TLR4\/NLRP3 Signaling. Cardiovasc Drugs Ther. May 31, 2023. doi:10.1007\/s10557-023-07464-x.","DOI":"10.1007\/s10557-023-07464-x"},{"issue":"3","key":"10.1016\/j.addr.2024.115361_b0305","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejheart.2008.01.004","article-title":"Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice","volume":"10","author":"Riad","year":"2008","journal-title":"Eur. J. Heart Fail."},{"issue":"13","key":"10.1016\/j.addr.2024.115361_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137102","article-title":"Mesenchymal stem cell-derived small extracellular vesicles protect cardiomyocytes from doxorubicin-induced cardiomyopathy by upregulating survivin expression via the miR-199a-3p-Akt-Sp1\/p53 signaling pathway","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2024.115361_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116794","article-title":"Resveratrol protects against doxorubicin-induced cardiotoxicity by attenuating ferroptosis through modulating the MAPK signaling pathway","volume":"482","author":"Chen","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"12","key":"10.1016\/j.addr.2024.115361_b0335","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s12276-020-00541-3","article-title":"Melatonin prevents doxorubicin-induced cardiotoxicity through suppression of AMPK\u03b12-dependent mitochondrial damage","volume":"52","author":"Yang","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0340","first-page":"H795","article-title":"Vitamin C mitigates oxidative\/nitrosative stress and inflammation in doxorubicin-induced cardiomyopathy","volume":"313","author":"Akolkar","year":"2017","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"key":"10.1016\/j.addr.2024.115361_b0360","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jconrel.2021.03.013","article-title":"pH-responsive polymersome-mediated delivery of doxorubicin into tumor sites enhances the therapeutic efficacy and reduces cardiotoxic effects","volume":"332","author":"Albuquerque","year":"2021","journal-title":"J. Control. Release"},{"issue":"23","key":"10.1016\/j.addr.2024.115361_b0350","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1158\/0008-5472.CAN-22-0734","article-title":"Doxorubicin-loaded polymeric meshes prevent local recurrence after sarcoma resection while avoiding cardiotoxicity","volume":"82","author":"Bressler","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2024.115361_b0380","doi-asserted-by":"crossref","unstructured":"Dorostkar H, Haghiralsadat BF, Hemati M, et al. Reduction of Doxorubicin-Induced Cardiotoxicity by Co-Administration of Smart Liposomal Doxorubicin and Free Quercetin: In Vitro and In Vivo Studies. Pharmaceutics. 2023;15(7). doi:10.3390\/pharmaceutics15071920.","DOI":"10.3390\/pharmaceutics15071920"},{"key":"10.1016\/j.addr.2024.115361_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122379","article-title":"A liposomal formulation of simvastatin and doxorubicin for improved cardioprotective and anti-cancer effect","volume":"629","author":"Bj\u00f8rnstad","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2024.115361_b0390","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.2147\/IJN.S372851","article-title":"Mesenchymal stem cell derived exosomes as nanodrug carrier of doxorubicin for targeted osteosarcoma therapy via SDF1-CXCR4 axis","volume":"17","author":"Wei","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2024.115361_b0370","article-title":"Light-responsive micelles loaded with doxorubicin for osteosarcoma suppression","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2024.115361_b0355","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.biomaterials.2016.02.001","article-title":"Synergistic anti-tumor activity through combinational intratumoral injection of an in-situ injectable drug depot","volume":"85","author":"Kim","year":"2016","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0415","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1038\/s41467-018-04763-y","article-title":"Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy","volume":"9","author":"Fan","year":"2018","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.addr.2024.115361_b0145","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1067\/mje.2002.120892","article-title":"The Tei index: A new prognostic index for patients with symptomatic heart failure","volume":"15","author":"Harjai","year":"2002","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0150","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/ERP-20-0013","article-title":"The role of the Tei index in assessing for cardiotoxicity from anthracycline chemotherapy: A systematic review","volume":"8","author":"Bennett","year":"2021","journal-title":"Echo Res. Pract."},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0155","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1634\/theoncologist.2007-0247","article-title":"Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy","volume":"13","author":"Kane","year":"2008","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.addr.2024.115361_b0160","doi-asserted-by":"crossref","first-page":"e008209","DOI":"10.1161\/CIRCHEARTFAILURE.120.008209","article-title":"Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II beta and not metal chelation","volume":"14","author":"Jirkovsk\u00fd","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.addr.2024.115361_b0165","unstructured":"Eneh C, Lekkala MR. Dexrazoxane. In: StatPearls. StatPearls Publishing; 2022."},{"key":"10.1016\/j.addr.2024.115361_b0170","unstructured":"Leek JC, Arif H. Pregnancy Medications. In: StatPearls. StatPearls Publishing; 2023."},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0175","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1081\/CNV-100103136","article-title":"Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy","volume":"19","author":"Gabizon","year":"2001","journal-title":"Cancer Invest."},{"issue":"17","key":"10.1016\/j.addr.2024.115361_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174421","article-title":"Anthracyclines strike back: Rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer","volume":"13","author":"Schettini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.addr.2024.115361_b0185","first-page":"970","article-title":"Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance","volume":"116","author":"Gy\u00f6ngy\u00f6si","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2024.115361_b0190","doi-asserted-by":"crossref","unstructured":"Pra\u00e7a FSG, Marinho HS, Martins MBF, Gaspar R, Corvo ML, Medina WSG. Current aspects of breast cancer therapy and diagnosis based on a nanocarrier approach. In: Nanostructures for Cancer Therapy. Elsevier; 2017:749-774. doi:10.1016\/B978-0-323-46144-3.00027-1.","DOI":"10.1016\/B978-0-323-46144-3.00027-1"},{"issue":"3","key":"10.1016\/j.addr.2024.115361_b0195","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/annonc\/mdt543","article-title":"Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer","volume":"25","author":"Baselga","year":"2014","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0200","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13048-022-01029-6","article-title":"Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.addr.2024.115361_b0205","doi-asserted-by":"crossref","unstructured":"Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. 2012;1(1):10. doi:10.1186\/2162-3619-1-10.","DOI":"10.1186\/2162-3619-1-10"},{"issue":"3","key":"10.1016\/j.addr.2024.115361_b0210","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ejhpharm-2020-002311","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: A literature review of pharmaceutical and clinical aspects","volume":"28","author":"Zhu","year":"2020","journal-title":"Eur. J. Hosp. Pharm. Sci. Pract."},{"issue":"2","key":"10.1016\/j.addr.2024.115361_b0215","doi-asserted-by":"crossref","first-page":"e230569","DOI":"10.1001\/jamanetworkopen.2023.0569","article-title":"Risk prediction models for cardiotoxicity of chemotherapy among patients with breast cancer: A systematic review","volume":"6","author":"Kabor\u00e9","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0220","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4103\/IJPC.IJPC_65_17","article-title":"Effect of aerobic exercise on cancer-related fatigue","volume":"23","author":"Patel","year":"2017","journal-title":"Indian J. Palliat. Care"},{"key":"10.1016\/j.addr.2024.115361_b0225","doi-asserted-by":"crossref","unstructured":"Smith WA, Ness KK, Joshi V, Hudson MM, Robison LL, Green DM. Exercise training in childhood cancer survivors with subclinical cardiomyopathy who were treated with anthracyclines. Pediatr Blood Cancer. November 6, 2013. doi:10.1002\/pbc.24850.","DOI":"10.1002\/pbc.24850"},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0230","first-page":"41","article-title":"Pre-diagnosis exercise and cardiovascular events in primary breast cancer","volume":"1","author":"Okwuosa","year":"2019","journal-title":"JACC: Cardiooncology"},{"issue":"2","key":"10.1016\/j.addr.2024.115361_b0235","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/XCE.0000000000000228","article-title":"Exercise, cancer and cardiovascular disease: what should clinicians advise?","volume":"10","author":"Zimmerman","year":"2021","journal-title":"Cardiovasc. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2024.115361_b0240","article-title":"Exercise cardio-oncology: Exercise as a potential therapeutic modality in the management of anthracycline-induced cardiotoxicity","volume":"8","author":"Kang","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0245","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaccao.2020.09.001","article-title":"Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: The CCTRN SENECA trial","volume":"2","author":"Bolli","year":"2020","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.addr.2024.115361_b0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ahj.2017.03.010","article-title":"Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial","volume":"188","author":"Guglin","year":"2017","journal-title":"Am. Heart J."},{"issue":"22","key":"10.1016\/j.addr.2024.115361_b0255","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.addr.2024.115361_b0260","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/modpathol.2013.251","article-title":"High EGFR gene copy number predicts poor outcome in triple-negative breast cancer","volume":"27","author":"Park","year":"2014","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0265","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1038\/s41598-023-30950-z","article-title":"A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer","volume":"13","author":"Mamot","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0275","doi-asserted-by":"crossref","first-page":"12060","DOI":"10.1038\/s41598-020-68907-1","article-title":"Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4","volume":"10","author":"Golforoush","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.addr.2024.115361_b0285","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00335-023-09977-0","article-title":"What to consider for ECG in mice-with special emphasis on telemetry","volume":"34","author":"Calvet","year":"2023","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.addr.2024.115361_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.603322","article-title":"CTRP5-overexpression attenuated ischemia-reperfusion associated heart injuries and improved infarction induced heart failure","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0295","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tem.2011.12.003","article-title":"CTRP family: Linking immunity to metabolism","volume":"23","author":"Sch\u00e4ffler","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.addr.2024.115361_b0310","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaccao.2021.05.006","article-title":"Mitochondria-rich extracellular vesicles rescue patient-specific cardiomyocytes from doxorubicin injury: Insights into the SENECA trial","volume":"3","author":"O\u2019Brien","year":"2021","journal-title":"JACC CardioOncol."},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0315","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12951-023-01973-5","article-title":"Extracellular vesicles: A rising star for therapeutics and drug delivery","volume":"21","author":"Du","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.addr.2024.115361_b0325","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jjcc.2018.10.002","article-title":"Progress and challenge of cardiac regeneration to treat heart failure","volume":"73","author":"Isomi","year":"2019","journal-title":"J. Cardiol."},{"issue":"6","key":"10.1016\/j.addr.2024.115361_b0345","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41569-020-00499-9","article-title":"Targeted delivery of therapeutic agents to the heart","volume":"18","author":"Sahoo","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.addr.2024.115361_b0365","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The role of biomarkers in cardio-oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.addr.2024.115361_b0375","doi-asserted-by":"crossref","first-page":"9246138","DOI":"10.1155\/2019\/9246138","article-title":"Malondialdehyde and uric acid as predictors of adverse outcome in patients with chronic heart failure","volume":"2019","author":"Romuk","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"7","key":"10.1016\/j.addr.2024.115361_b0395","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076615","article-title":"Liposomes in cancer therapy: How did we start and where are we now","volume":"24","author":"Fulton","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2024.115361_b0400","doi-asserted-by":"crossref","unstructured":"Wang AZ. EPR or no EPR? The billion-dollar question. Sci Transl Med. 2015;7(294):294ec112-294ec112. doi:10.1126\/scitranslmed.aac8108.","DOI":"10.1126\/scitranslmed.aac8108"},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0405","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.addr.2024.115361_b0410","doi-asserted-by":"crossref","first-page":"e6800","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.addr.2024.115361_b0420","first-page":"36","article-title":"Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia","volume":"7","author":"Vachhani","year":"2017","journal-title":"Leuk. Res. Rep."},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0425","first-page":"e37308","article-title":"Efficacy of dexrazoxane in cardiac protection in pediatric patients treated with anthracyclines","volume":"15","author":"Rahimi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.addr.2024.115361_b0430","doi-asserted-by":"crossref","unstructured":"de Baat EC, Mulder RL, Armenian S, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. 2022;9(9):CD014638. doi:10.1002\/14651858.CD014638.pub2.","DOI":"10.1002\/14651858.CD014638.pub2"},{"issue":"4","key":"10.1016\/j.addr.2024.115361_b0435","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.addr.2024.115361_b0440","doi-asserted-by":"crossref","first-page":"2102841","DOI":"10.1155\/2020\/2102841","article-title":"Roles of reactive oxygen species in cardiac differentiation, reprogramming, and regenerative therapies","volume":"2020","author":"Liang","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0445","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0253-7613.91871","article-title":"Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats","volume":"44","author":"Swamy","year":"2012","journal-title":"Indian J. Pharmacol."},{"issue":"3","key":"10.1016\/j.addr.2024.115361_b0450","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/CIRCULATIONAHA.121.058655","article-title":"Direct reprogramming improves cardiac function and reverses fibrosis in chronic myocardial infarction","volume":"147","author":"Tani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2024.115361_b0455","first-page":"29","article-title":"Cardiac fibrosis in oncologic therapies","author":"Packard","year":"2022","journal-title":"Curr. Opin. Physiol."},{"issue":"2","key":"10.1016\/j.addr.2024.115361_b0460","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ehf2.12616","article-title":"Reactive fibrosis precedes doxorubicin-induced heart failure through sterile inflammation","volume":"7","author":"Tanaka","year":"2020","journal-title":"ESC Heart Fail."},{"issue":"15","key":"10.1016\/j.addr.2024.115361_b0465","doi-asserted-by":"crossref","first-page":"e020243","DOI":"10.1161\/JAHA.120.020243","article-title":"Morphological plaque characteristics and clinical outcomes in patients with acute coronary syndrome and a cancer history","volume":"10","author":"Tanimura","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.addr.2024.115361_b0470","unstructured":"Hufnagle JJ, Andersen SN, Maani EV. Radiation-Induced Cardiac Toxicity. In: StatPearls. StatPearls Publishing; 2023."},{"issue":"11","key":"10.1016\/j.addr.2024.115361_b0475","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: Systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.addr.2024.115361_b0480","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/COH.0000000000000702","article-title":"Cardiovascular toxicity of contemporary antiretroviral therapy","volume":"16","author":"Vos","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1","key":"10.1016\/j.addr.2024.115361_b0485","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol."},{"issue":"11","key":"10.1016\/j.addr.2024.115361_b0490","first-page":"e19658","article-title":"Pediatric chemotherapy drugs associated with cardiotoxicity","volume":"13","author":"Hitawala","year":"2021","journal-title":"Cureus"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X24001832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X24001832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T04:37:36Z","timestamp":1728275856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X24001832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":98,"alternative-id":["S0169409X24001832"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2024.115361","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2024.115361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115361"}}